Neuronetics Q2 rev $38.1M (+132% YoY); secures $10M additional debt; lowers liquidity requirement to $2M through Sep'26

Neuronetics, Inc.

Q2 2025 revenue $38.1M, up 132% YoY; adjusted pro forma growth 18%; net loss $(9.8)M ($0.15 loss per share).
Record Greenbrook clinic revenue $23.0M; U.S. treatment session revenue $10.8M (pro forma +13%); shipped 41 NeuroStar systems.
Received $10M Tranche 2A loan from Perceptive on Aug 1, 2025; minimum liquidity lowered to $2M through Sep 2026; still eligible for $5M more.
Appointed Steven Pfanstiel as CFO effective July 15, 2025; succeeded Stephen Furlong.
Guidance: Q3 rev $37-39M, FY rev $149-155M; FY operating expenses raised to $100-105M; cash flow positive expected in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.